OKYO Pharma to Present at BIO-Europe 2025 in Vienna

Summary by AI BETAClose X

OKYO Pharma Limited announced that its CEO will present at the 33rd Annual BIO-Europe partnering conference from November 3-5, 2025, in Vienna, Austria. The presentation will focus on OKYO's lead investigational candidate, urcosimod, and provide updates on the company's recently completed Phase 2 clinical trial for the treatment of neuropathic corneal pain. The OKYO management team will also participate in one-on-one partnering meetings to discuss clinical milestones, including recent positive clinical data for urcosimod and the acceleration of its clinical development program. Urcosimod is currently being evaluated in a recently completed randomized, placebo-controlled, double-masked Phase 2 trial involving 17 neuropathic corneal pain patients.

Disclaimer*

UK 100

Latest directors dealings